Table 1 Patient demographics for implanted esophageal cancer tumors

From: Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment

Characteristics

Adenocarcinoma (n=54)

Squamous cell carcinoma (n=16)

P-valuea

All tumors (n=70)

Mean age (range)

63 (44–87)

66 (46–85)

0.45b

63.7 (43.8–86.5)

Disease-free survival time

    

Median (years)

1.4

DNR

0.28c

1.45

Sex

 Male

41 (76%)

11 (69%)

0.54

52 (74%)

 Female

13 (24 %)

5 (31%)

 

18 (26%)

Pathological stage

 1–2

19 (35%)

11 (69%)

0.02

30 (43%)

 3–4

35 (65%)

5 (31%)

 

40 (57%)

Differentiation d

 Poor

22 (41%)

3 (19%)

0.22

25 (36%)

 Moderate/well

29 (54%)

11 (69%)

 

39 (56%)

Location of malignancy

 Upper esophagus

0

1 (6 %)

 

1 (1%)

 Middle esophagus

2 (4%)

7 (44%)

<0.001

9 (13%)

 Lower esophagus

10 (19%)

6 (38%)

 

16 (23%)

 GEJ

42 (78%)

2 (13%)

 

44 (63%)

Neo-adjuvant chemo-rad

 Yes

24 (44%)

5 (31%)

0.51

29 (41%)

 No

30 (56%)

11 (69%)

 

41 (59%)

History of heartburn

 Yes

26 (48%)

N/A

N/A

N/A

 No

28 (52%)

   

Barrett’s esophagus

 Yes

13 (24%)

N/A

N/A

N/A

 No

41 (76%)

   

Smoking status

    

 Current smoker

5 (9%)

2 (13%)

 

7 (10%)

 Ex-smoker

30 (56%)

9 (56%)

0.9

39 (56%)

 Never smoker

19 (35%)

5 (31%)

 

24 (34%)

Alcohol consumption d

 Current drinker

 

7 (44%)

  

 Ex-drinker

N/A

2 (13%)

N/A

N/A

 Never drinker

 

2 (13%)

  
  1. Abbreviations: GEJ, gastro-esophageal junction; N/A, not applicable.
  2. aFisher’s exact test unless otherwise stated; comparing adenocarcinoma and squamous cell carcinoma.
  3. bStudent’s t-test.
  4. cLog-rank test.
  5. dPatients with no available information were not included in the calculation.
Back to article page